Aliko Scientific's Brazilian Gambit: A Vertical Integration Play in LatAm

PARIS, France – September 15, 2026 – In a strategic move that signals a significant shift in its operating model, Paris-based Aliko Scientific (Euronext Growth: ALIKO) has announced a major expansion into South America with the launch of its Probantes project in Brazil. The initiative involves establishing a new, wholly-owned subsidiary, Probantes Ltda, and forging a strategic industrial cooperation with local firm Biodetecta – Life Science Ltda. While on the surface a life sciences play, the move offers a compelling case study for institutional investors and market analysts on how companies can engineer a pivot towards vertical integration and recurring revenue streams in high-growth emerging markets.

This isn't merely an expansion; it's a fundamental re-architecting of Aliko’s value proposition. The company is transitioning from a portfolio of complementary diagnostic technologies into a vertically integrated oncology platform that combines equipment, software, and, most critically, proprietary consumables. This strategic pivot aims to capture more value from its installed base and build a more predictable, scalable business model—a playbook familiar to many successful technology firms.

A Strategic Pivot to Recurring Revenue

At the heart of the Brazilian venture is a clear objective to transform Aliko Scientific’s revenue structure. The company, which specializes in integrated oncology diagnostics through its Ikonisys and Hospitex subsidiaries, has historically relied on the sale of diagnostic equipment. The establishment of Probantes is designed to change that by creating a recurring revenue engine tied directly to its technology.

Francesco Trisolini, CEO of Aliko Scientific, articulated the vision clearly: "Probantes fills a critical technological gap in our portfolio by adding proprietary FISH probes to Aliko Scientific’s integrated diagnostic platform. This strengthens the value of our installed base by creating recurring consumable revenues linked to every test performed, while increasing the lifetime value of each system placed with customers."

This move to develop proprietary Fluorescence In Situ Hybridization (FISH) probes—essential consumables for advanced cancer diagnostics—is pivotal. By controlling the production of these high-margin reagents, Aliko not only secures its supply chain but also gains the ability to implement more flexible and modern commercial models. Trisolini explicitly pointed to developing solutions like "pay-per-use, pay-per-test, pay-per-report and service-based solutions." This language mirrors the service-based models that have become the gold standard in the software and fintech industries, demonstrating a forward-thinking approach to monetizing hardware and intellectual property.

For investors, this signals a shift from lumpy, capital-intensive equipment sales to a more stable, predictable, and scalable revenue model. This transition, if successful, could significantly de-risk the company's financial profile and improve margins over the long term, making it a more attractive proposition for institutional portfolios.

Capturing a High-Growth Emerging Market

The choice of Brazil as the beachhead for this strategic pivot is no accident. The South American oncology diagnostics market is on a steep growth trajectory, fueled by an aging population, rising cancer incidence, and expanding healthcare infrastructure. Market research projects the Brazilian cancer diagnostics market, valued at over $5.5 billion in 2025, to surge past $9.2 billion by 2033, registering a compound annual growth rate (CAGR) of around 6.5%. Critically, consumables represent the largest and fastest-growing segment, validating Aliko's strategic focus.

By establishing Probantes in Anápolis, Goiás—one of Brazil’s most important pharmaceutical and life sciences industrial clusters—Aliko is embedding itself within a thriving local ecosystem. The partnership with Biodetecta – Life Science Ltda is a masterstroke in de-risking market entry. It provides Aliko with immediate access to local manufacturing infrastructure, regulatory know-how, and molecular biology expertise without the time and capital expenditure required to build from scratch.

"The agreement with Biodetecta gives us immediate access to experienced local manufacturing capabilities and molecular biology expertise," Trisolini noted, emphasizing that the intellectual property and international commercial rights will remain with Aliko. This structure allows the company to leverage local talent and infrastructure while retaining control over its most valuable assets—a model for smart international expansion.

An Innovative Financial and Operational Architecture

The partnership's structure is as innovative as its strategic goals. The cooperation is organized through a Brazilian Sociedade em Conta de Participação (SCP), a contractual vehicle that allows for project-specific governance and segregated accounting without creating a separate legal entity. This sophisticated arrangement provides Aliko with contractual control over key strategic and economic aspects of the project.

Under the terms, profits generated within the SCP will be allocated 51% to Aliko's Probantes and 49% to Biodetecta. However, these profits are expected to be reinvested to fuel working capital, product development, and further expansion, demonstrating a long-term commitment from both partners. This financial architecture aligns incentives while ensuring that the venture is self-sustaining and focused on growth.

The commercial arrangement is equally strategic. Biodetecta will hold the commercialization rights for the new products within Brazil, leveraging its local market knowledge. Meanwhile, Aliko Scientific retains exclusive rights for all markets outside Brazil, positioning Probantes as a global production hub and a launchpad for its entire diagnostic portfolio across Latin America.

This venture comes as Aliko Scientific continues to execute a broader global strategy. The company recently announced a collaboration to accelerate its U.S. expansion and signed new distribution agreements in Romania and Saudi Arabia. These moves, coupled with a recent capital raise of approximately €688k, paint a picture of a company aggressively pursuing a multi-pronged growth strategy. Navigating Brazil's complex regulatory landscape, governed by the stringent ANVISA agency and its recently updated IVD mandates like RDC 830/2023, will be a key challenge. However, the partnership with a local expert like Biodetecta is designed precisely to mitigate this risk, turning a potential hurdle into a competitive advantage. For Aliko Scientific, the Probantes project is far more than a new subsidiary; it is the cornerstone of its ambition to become a vertically integrated global leader in oncology diagnostics.